Informations générales (source: ClinicalTrials.gov)
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Interventional
Phase 3
Annexon, Inc. (Voir sur ClinicalTrials)
juillet 2024
octobre 2027
02 décembre 2025
The primary purpose of the study is to determine if IVT injections of vonaprument every
month reduce vision loss in participants with GA secondary to age-related macular
degeneration (AMD).
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Eric SOUIED | 28/08/2025 14:50:04 | Contacter | ||
Critères
Tous
- Diagnosis of GA of the macula secondary to AMD as determined by the Investigator and
confirmed by the independent Central Reading Center.
Exclusion Criteria:
- Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod
dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil
maculopathy) in either eye.
NOTE: Other protocol-defined inclusion and exclusion criteria may apply.